Compare Aurobindo Pharma with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs AJANTA PHARMA - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA AJANTA PHARMA AUROBINDO PHARMA/
AJANTA PHARMA
 
P/E (TTM) x 10.9 20.4 53.3% View Chart
P/BV x 1.4 4.8 29.7% View Chart
Dividend Yield % 0.7 0.6 132.8%  

Financials

 AUROBINDO PHARMA   AJANTA PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-21
AJANTA PHARMA
Mar-21
AUROBINDO PHARMA/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,0231,883 54.3%   
Low Rs3331,258 26.5%   
Sales per share (Unadj.) Rs422.8334.0 126.6%  
Earnings per share (Unadj.) Rs92.075.6 121.7%  
Cash flow per share (Unadj.) Rs110.089.0 123.6%  
Dividends per share (Unadj.) Rs4.009.50 42.1%  
Avg Dividend yield %0.60.6 97.5%  
Book value per share (Unadj.) Rs374.3346.1 108.1%  
Shares outstanding (eoy) m585.9486.53 677.2%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x1.64.7 34.1%   
Avg P/E ratio x7.420.8 35.5%  
P/CF ratio (eoy) x6.217.7 34.9%  
Price / Book Value ratio x1.84.5 39.9%  
Dividend payout %4.312.6 34.6%   
Avg Mkt Cap Rs m397,398135,898 292.4%   
No. of employees `000NANA-   
Total wages/salary Rs m35,3505,483 644.8%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m247,74628,897 857.3%  
Other income Rs m3,809260 1,465.9%   
Total revenues Rs m251,55529,157 862.8%   
Gross profit Rs m81,4809,986 816.0%  
Depreciation Rs m10,5541,161 909.1%   
Interest Rs m74583 900.7%   
Profit before tax Rs m73,9909,002 821.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m20,0982,463 816.0%   
Profit after tax Rs m53,8926,539 824.2%  
Gross profit margin %32.934.6 95.2%  
Effective tax rate %27.227.4 99.3%   
Net profit margin %21.822.6 96.1%  
BALANCE SHEET DATA
Current assets Rs m198,23522,178 893.8%   
Current liabilities Rs m106,6528,388 1,271.4%   
Net working cap to sales %37.047.7 77.5%  
Current ratio x1.92.6 70.3%  
Inventory Days Days1953 36.4%  
Debtors Days Days529 553.4%  
Net fixed assets Rs m135,77818,912 717.9%   
Share capital Rs m586174 336.9%   
"Free" reserves Rs m218,71329,777 734.5%   
Net worth Rs m219,29929,951 732.2%   
Long term debt Rs m1,68416 10,525.0%   
Total assets Rs m334,01341,090 812.9%  
Interest coverage x100.3109.8 91.3%   
Debt to equity ratio x00 1,437.5%  
Sales to assets ratio x0.70.7 105.5%   
Return on assets %16.416.1 101.5%  
Return on equity %24.621.8 112.6%  
Return on capital %33.830.3 111.6%  
Exports to sales %53.80-   
Imports to sales %16.40-   
Exports (fob) Rs m133,248NA-   
Imports (cif) Rs m40,615NA-   
Fx inflow Rs m133,24818,097 736.3%   
Fx outflow Rs m44,9462,315 1,941.9%   
Net fx Rs m88,30215,782 559.5%   
CASH FLOW
From Operations Rs m33,2895,763 577.6%  
From Investments Rs m5,987-2,824 -212.0%  
From Financial Activity Rs m-13,648-3,183 428.8%  
Net Cashflow Rs m25,831-244 -10,599.5%  

Share Holding

Indian Promoters % 48.8 70.5 69.2%  
Foreign collaborators % 3.1 0.0 -  
Indian inst/Mut Fund % 38.3 21.4 179.1%  
FIIs % 20.8 8.6 241.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 48.2 29.5 163.2%  
Shareholders   338,639 60,759 557.3%  
Pledged promoter(s) holding % 14.9 16.6 90.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CIPLA    SUN PHARMA    LUPIN    DR. REDDYS LAB    ZYDUS LIFESCIENCES    



Today's Market

Sensex Ends 236 Points Lower, Nifty Falls Below 16,150; IT & FMCG Stocks Witness Selling(Closing)

Indian share markets ended on a negative note today as global cues remained weak.

Related Views on News

Aurobindo Pharma Rallies on Sale of Injectables Unit to Subsidiary (Views On News)

Jul 2, 2021

Here's why the company sold its business unit to Eugia Pharma Specialities.

Aurobindo Pharma's Stock Falls After Profits Decline 7% (Views On News)

Jun 1, 2021

Aurobindo Pharma shares fell nearly 4% after quarterly earnings disappoint.

Why Divi's Lab Share Price is Falling (Views On News)

May 24, 2022

Here's why Divi's Lab's stock fell over 10% in two days.

Divi's Lab Net Profit Rises 78%. Company Declares 1,500% Dividend (Views On News)

May 23, 2022

For full year, profit figures stood at Rs 29.6 bn as against Rs 19.8 bn for the previous year, reflecting a growth of 49%.

Dr Reddy's Net Profit Falls 76%. Company Declares 600% Dividend (Views On News)

May 19, 2022

During Q4, there were many changes to the products forming part of Dr Reddy's generics and proprietary products segments.

More Views on News

Most Popular

2022's Best Performing Penny Stocks So Far...(Views On News)

Mar 2, 2022

We are just two months into 2022 and several penny stocks that we track have already surged 5x.

5 Debt Free Penny Stocks with Good Profitability to Watch Out for in 2022(Views On News)

Mar 16, 2022

Debt free penny stocks are vital when it's a question of portfolio diversification in a volatile market. They can potentially offer good profitability in the long run.

Penny Stocks to Buy and Hold Beyond 2022(Views On News)

Apr 6, 2022

A step-by-step method to pick the best penny stocks for the long term.

6 Penny Stocks that Could Be Hidden Bluechips. Take a Look...(Views On News)

Apr 13, 2022

These penny stocks can become future multibaggers. Watch out for them.

Adani Power vs Tata Power: Which Power Stock is Better?(Views On News)

Feb 28, 2022

Rising electricity consumption provides a lot of scope for growth. Which company has a better chance at capturing it?

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


May 24, 2022 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 5-YR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS